Cargando…
How antimalarial drug resistance affects post-treatment prophylaxis
Slowly eliminated antimalarial drugs suppress malaria reinfections for a period of time determined by the dose, the pharmacokinetic properties of the drug, and the susceptibility of the infecting parasites. This effect is called post-treatment prophylaxis (PTP). The clinical benefits of preventing r...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254426/ https://www.ncbi.nlm.nih.gov/pubmed/18186948 http://dx.doi.org/10.1186/1475-2875-7-9 |
_version_ | 1782151186506317824 |
---|---|
author | White, Nicholas J |
author_facet | White, Nicholas J |
author_sort | White, Nicholas J |
collection | PubMed |
description | Slowly eliminated antimalarial drugs suppress malaria reinfections for a period of time determined by the dose, the pharmacokinetic properties of the drug, and the susceptibility of the infecting parasites. This effect is called post-treatment prophylaxis (PTP). The clinical benefits of preventing recrudescence (reflecting treatment efficacy) compared with preventing reinfection (reflecting PTP) need further assessment. Antimalarial drug resistance shortens PTP. While blood concentrations are in the terminal elimination phase, the degree of shortening may be estimated from measurements of in-vitro susceptibility and the terminal elimination half-life. More information is needed on PTP following intermittent preventive treatments, and on the relationship between the duration of PTP and immunity, so that policy recommendations can have a firmer evidence base. |
format | Text |
id | pubmed-2254426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22544262008-02-26 How antimalarial drug resistance affects post-treatment prophylaxis White, Nicholas J Malar J Review Slowly eliminated antimalarial drugs suppress malaria reinfections for a period of time determined by the dose, the pharmacokinetic properties of the drug, and the susceptibility of the infecting parasites. This effect is called post-treatment prophylaxis (PTP). The clinical benefits of preventing recrudescence (reflecting treatment efficacy) compared with preventing reinfection (reflecting PTP) need further assessment. Antimalarial drug resistance shortens PTP. While blood concentrations are in the terminal elimination phase, the degree of shortening may be estimated from measurements of in-vitro susceptibility and the terminal elimination half-life. More information is needed on PTP following intermittent preventive treatments, and on the relationship between the duration of PTP and immunity, so that policy recommendations can have a firmer evidence base. BioMed Central 2008-01-11 /pmc/articles/PMC2254426/ /pubmed/18186948 http://dx.doi.org/10.1186/1475-2875-7-9 Text en Copyright © 2008 White; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review White, Nicholas J How antimalarial drug resistance affects post-treatment prophylaxis |
title | How antimalarial drug resistance affects post-treatment prophylaxis |
title_full | How antimalarial drug resistance affects post-treatment prophylaxis |
title_fullStr | How antimalarial drug resistance affects post-treatment prophylaxis |
title_full_unstemmed | How antimalarial drug resistance affects post-treatment prophylaxis |
title_short | How antimalarial drug resistance affects post-treatment prophylaxis |
title_sort | how antimalarial drug resistance affects post-treatment prophylaxis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254426/ https://www.ncbi.nlm.nih.gov/pubmed/18186948 http://dx.doi.org/10.1186/1475-2875-7-9 |
work_keys_str_mv | AT whitenicholasj howantimalarialdrugresistanceaffectsposttreatmentprophylaxis |